中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

31 records (took 0.037 seconds)

    MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
    11.
    发明申请
    MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE 审中-公开
    至少一种芬替康的形式的改性释放组合物

    公开(公告)号：US20090269402A1

    公开(公告)日：2009-10-29

    申请号：US12425972

    申请日：2009-04-17

    Applicant: Fang ZHOU ,  Werner Oberegger ,  Paul Maes

    Inventor： Fang ZHOU ,  Werner Oberegger ,  Paul Maes

    IPC: A61K9/24 ,  A61K31/135

    CPC classification number: A61K9/2027 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/284 ,  A61K9/2866

    Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

    Abstract translation: 本发明涉及至少一种形式的文拉法辛的缓释组合物，其是延迟的控释组合物。 所述组合物包含至少一种文拉法辛的核心，其选自文拉法辛，文拉法辛的活性代谢物，文拉法辛的药学上可接受的盐，文拉法辛的活性代谢物的药学上可接受的盐及其组合，小于 10％胶凝剂和药学上可接受的赋形剂。 组合物还包含基本上围绕芯的改性释放包衣，其提供至少一种形式的文拉法辛的延迟控制释放。

    MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM
    12.
    发明申请
    MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM 审中-公开
    多功能运输系统

    公开(公告)号：US20090004281A1

    公开(公告)日：2009-01-01

    申请号：US11768764

    申请日：2007-06-26

    Applicant: Tien Nghiem ,  Graham JACKSON

    Inventor： Tien Nghiem ,  Graham JACKSON

    IPC: A61K9/50 ,  A61K31/27 ,  A61K31/428 ,  A61P25/16 ,  A61P9/06 ,  A61P25/28 ,  A61P25/00 ,  A61K31/554

    CPC classification number: A61K31/428 ,  A61K9/0004 ,  A61K31/27 ,  A61K31/554

    Abstract: The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core.

    Abstract translation: 本发明涉及多颗粒渗透递送系统。 该系统是适于口服给药的改良释放组合物。 组合物包括与至少一种药学上可接受的赋形剂组合的至少一种药物的核心。 组合物还包括围绕芯的渗透性底涂层和围绕渗透性底涂芯的改性释放外涂层。

    EXTENDED RELEASE FORMULATIONS OF CARVEDILOL
    14.
    发明申请
    EXTENDED RELEASE FORMULATIONS OF CARVEDILOL 审中-公开
    卡维地洛的延长释放配方

    公开(公告)号：US20080138404A1

    公开(公告)日：2008-06-12

    申请号：US11945422

    申请日：2007-11-27

    Applicant: Edwin WALSH ,  Ann Marie YOUNG ,  Graham JACKSON

    Inventor： Edwin WALSH ,  Ann Marie YOUNG ,  Graham JACKSON

    IPC: A61K9/22 ,  A61K31/403 ,  A61K9/52

    CPC classification number: A61K31/403 ,  A61K9/2031

    Abstract: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

    Abstract translation: 描述了一种每日一次给予卡维地洛的改进的控释剂型。 控释剂型包含治疗有效量的卡维地洛和/或其药学上可接受的盐; 一种或多种亲水聚合物; 一种或多种药学上可接受的赋形剂; 和聚氧化烯嵌段共聚物，卡​​维地洛的固体分散体和挤出材料或聚氧化烯嵌段共聚物，卡​​维地洛的固体分散体和挤出材料的组合。

    Chronotherapeutic diltiazem formulations and the administration thereof
    16.
    发明申请
    Chronotherapeutic diltiazem formulations and the administration thereof 审中-公开
    计时治疗性地尔硫卓制剂及其施用

    公开(公告)号：US20060153914A1

    公开(公告)日：2006-07-13

    申请号：US11370842

    申请日：2006-03-09

    Applicant: Kenneth Albert ,  Paul Maes

    Inventor： Kenneth Albert ,  Paul Maes

    IPC: A61K31/553 ,  A61K9/22

    CPC classification number: A61K9/5078 ,  A61K9/2081 ,  A61K31/553

    Abstract: A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

    Abstract translation: 药物可接受的地尔硫卓的控释制剂，包括其药学上可接受的盐，适合每24小时晚间给药，含有约120mg至约540mg或更多（如所需）与赋形剂相关的地尔硫卓形式，以提供受控制 （持续）释放形式的地尔硫卓，在给药后约10小时至约15小时之间，在血液中提供地塞米松的最大值，该制剂包含口服持续释放的地尔硫卓形式 剂量形式，其中地尔硫卓适于在长时间施用后释放，并在给予人时显示（i）在晚上给予时比在早晨没有食物时根据FDA指南或标准给予更高的生物利用度 和（ii）根据相同的FDA指导方针或标准，早晨给予和不含食物时，生物等效性。

    PHARMACEUTICAL COMPOSITION
    17.
    发明申请
    PHARMACEUTICAL COMPOSITION 审中-公开
    药物组合物

    公开(公告)号：US20110052684A1

    公开(公告)日：2011-03-03

    申请号：US12864453

    申请日：2009-01-28

    Applicant: Edwin Walsh ,  Graham Jackson ,  Werner Oberegger ,  Xiaopin Jin

    Inventor： Edwin Walsh ,  Graham Jackson ,  Werner Oberegger ,  Xiaopin Jin

    IPC: A61K31/343 ,  A61K9/22 ,  A61K9/00 ,  A61P25/24 ,  A61P25/22

    CPC classification number: A61K9/2866 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/284 ,  A61K9/5084 ,  A61K31/137 ,  A61K31/343 ,  A61K31/554 ,  A61K2300/00

    Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

    Abstract translation: 本发明涉及一种药物组合物，其包含片芯，其包含选自盐酸安非他酮和草酸依托普兰，安非他酮氢溴酸盐和西酞普兰盐酸盐，安非他酮氢溴酸盐和草酸依托普兰以及安非他酮氢溴酸盐和喹硫平， 和至少一种药学上可接受的赋形剂和围绕片芯的对照释放包衣，其中所述组合物令人惊奇地提供了体外活性剂组合的同步释放。 每天一次的药物组合物令人惊奇地还提供了当给予需要这种给药的受试者时，加强安非他酮氢溴酸盐的吸收。

    CONTROLLED RELEASE DOSAGE FORMS
    18.
    发明申请
    CONTROLLED RELEASE DOSAGE FORMS 有权
    控制释放剂量形式

    公开(公告)号：US20090142378A1

    公开(公告)日：2009-06-04

    申请号：US12328828

    申请日：2008-12-05

    Applicant: Steven FRISBEE

    Inventor： Steven FRISBEE

    IPC: A61K9/00 ,  A61K47/30 ,  A61K31/155

    CPC classification number: A61K9/2893 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/135

    Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

    Abstract translation: 本发明提供用于涂覆药物口服剂型的稳定的控释单片涂料组合物，其包含熔点大于55℃的聚二醇和缺乏官能团的中性酯共聚物的水分散体。

    CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF
    19.
    发明申请
    CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF 审中-公开
    氯吡格雷配方及其治疗

    公开(公告)号：US20090118256A1

    公开(公告)日：2009-05-07

    申请号：US11952343

    申请日：2007-12-07

    Applicant: Kenneth Stephen ALBERT ,  Theophilus Jones Gana ,  Paul Maes

    Inventor： Kenneth Stephen ALBERT ,  Theophilus Jones Gana ,  Paul Maes

    IPC: A61K31/554 ,  A61P9/10

    CPC classification number: A61K31/55 ,  A61K9/2081 ,  A61K9/4866 ,  A61K9/5031 ,  A61K9/5047

    Abstract: A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

    Abstract translation: 一种在有需要的患者中治疗或预防心肌缺血的方法，包括施用药学上可接受的地尔硫卓的可释放的Galenical制剂，包括其药学上可接受的盐，适合于每24小时进行晚间给药，其含有约180mg至约420mg 与给药相关的地尔硫卓形式，以提供受控（持续）的地尔硫卓形式的释放，用于在给药后约10小时至约17小时之间在血液中提供地塞米松的C max，所述制剂包含口服的地尔硫卓形式 持续释放剂型，其中地尔硫卓适于在长时间给药后释放，并在给予人时显示（i）当晚上给予时，与根据FDA没有食物的早晨相比，具有较高的生物利用度 准则或标准，以及（ii）早晨给予的机智的生物等效性 根据相同的FDA指导方针或标准，可以获得食物。

Patent Agency Ranking